Medicare Enrolled
Dr. Gamini Sooriyaarachchi, M.D.
Hematology · Cape Coral, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Sooriyaarachchi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sooriyaarachchi? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sooriyaarachchi
Dr. Gamini Sooriyaarachchi is a hematology in Cape Coral, FL, with 20 years in practice. Based on federal Medicare data, Dr. Sooriyaarachchi performed 198,989 Medicare services across 5,183 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sooriyaarachchi received a total of $12,708 from 66 pharmaceutical and/or device companies across 702 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sooriyaarachchi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 20% volume in FL$ $12,708 industry payments
Medicare Practice Summary
Medicare Utilization ↗198,989
Medicare services
Top 20% in FL for hematology
5,183
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,949 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 31,110 | $0 | $4 |
| Filgrastim injection (Zarxio) for white blood cells | 21,180 | $0 | $2 |
| Iron sucrose injection (Venofer) | 19,900 | $0 | $5 |
| Azacitidine chemotherapy injection | 19,100 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 19,100 | $43 | $137 |
| Nivolumab injection (Opdivo) | 15,920 | $24 | $72 |
| Epoetin alfa injection (Procrit) for anemia | 14,500 | $6 | $23 |
| Oxaliplatin chemotherapy injection | 12,612 | $0 | $12 |
| Anti-nausea injection (aprepitant) | 11,180 | $1 | $5 |
| Denosumab injection (Prolia/Xgeva) | 6,720 | $18 | $51 |
| Daratumumab injection (Darzalex) | 6,300 | $38 | $110 |
| Immune globulin infusion (Gammagard) | 3,850 | $36 | $108 |
| Complete blood count (CBC) with differential | 3,133 | $8 | $29 |
| Blood draw (venipuncture) | 2,751 | $8 | $9 |
| Dexamethasone injection (steroid) | 1,828 | $0 | $3 |
| Office visit, established patient (30-39 min) | 1,515 | $98 | $339 |
| Drug injection, under skin or into muscle | 1,367 | $11 | $69 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,140 | $1 | $28 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 563 | $1 | $6 |
| Injection of additional new drug or substance into vein | 502 | $12 | $61 |
| Injection, leucovorin calcium, per 50 mg | 443 | $3 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 430 | $103 | $378 |
| Injection, fluorouracil, 500 mg | 353 | $2 | $7 |
| Anti-nausea injection (ondansetron/Zofran) | 352 | $0 | $9 |
| Hospital follow-up visit, moderate complexity | 333 | $65 | $197 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 268 | $50 | $189 |
| Injection, carboplatin, 50 mg | 236 | $2 | $41 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 159 | $58 | $206 |
| Injection, diphenhydramine hcl, up to 50 mg | 147 | $1 | $3 |
| Infusion, normal saline solution , 1000 cc | 147 | $2 | $7 |
| Office visit, established patient (20-29 min) | 133 | $64 | $239 |
| Administration of chemotherapy into vein, each additional hour | 132 | $22 | $79 |
| Infusion into a vein for hydration, each additional hour | 126 | $10 | $42 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 118 | $16 | $56 |
| Infusion into a vein for hydration, 31-60 minutes | 114 | $26 | $156 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 104 | $23 | $84 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 101 | $18 | $59 |
| Injection of drug or substance into vein | 89 | $30 | $156 |
| Initial hospital admission, high complexity | 85 | $142 | $556 |
| Injection, magnesium sulfate, per 500 mg | 72 | $1 | $2 |
| Administration of additional new drug or substance into vein, 1 hour or less | 70 | $52 | $178 |
| Initial hospital admission, moderate complexity | 62 | $107 | $377 |
| New patient office visit (45-59 min) | 61 | $121 | $453 |
| Office visit, established patient, complex (40-54 min) | 61 | $137 | $474 |
| Administration of additional new drug or substance into vein using push technique | 60 | $45 | $170 |
| Drawing of blood for a medical problem | 57 | $72 | $277 |
| Red blood count automated, with additional calculations | 55 | $5 | $20 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 51 | $27 | $89 |
| Automated urinalysis | 49 | $2 | $8 |
| Red blood count, automated test | 48 | $4 | $10 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 46 | $3 | $11 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 42 | $136 | $637 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 40 | $1 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 32 | $16 | $56 |
| New patient office visit, complex (60-74 min) | 16 | $171 | $585 |
| Hospital follow-up visit, low complexity | 13 | $41 | $109 |
| Hospital follow-up visit, high complexity | 13 | $97 | $285 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
18.1% high complexity
77.6% medium
4.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,708
Total received (2018-2024)
Avg $1,815/year across 7 years
Top 38% in FL for hematology
66
Companies
702
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,608 (99.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$100 (0.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,679
2023$1,517
2022$1,880
2021$1,236
2020$1,900
2019$2,338
2018$1,158
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$1,305
E.R. Squibb & Sons, L.L.C.
$1,276
Merck Sharp & Dohme Corporation
$978
PFIZER INC.
$754
Merck Sharp & Dohme LLC
$711
Novartis Pharmaceuticals Corporation
$662
Celgene Corporation
$650
AstraZeneca Pharmaceuticals LP
$458
Genentech USA, Inc.
$436
Gilead Sciences, Inc.
$405
GlaxoSmithKline, LLC.
$367
Incyte Corporation
$307
Daiichi Sankyo Inc.
$283
Amgen Inc.
$276
Lilly USA, LLC
$227
GENZYME CORPORATION
$226
Teva Pharmaceuticals USA, Inc.
$216
BeiGene USA, Inc.
$208
TAIHO ONCOLOGY, INC.
$202
Puma Biotechnology, Inc.
$190
Exelixis Inc.
$179
Bayer HealthCare Pharmaceuticals Inc.
$171
Takeda Pharmaceuticals U.S.A., Inc.
$152
ARRAY BIOPHARMA INC
$147
Astellas Pharma US Inc
$140
Clovis Oncology, Inc.
$130
Pharmacyclics LLC, An AbbVie Company
$102
COMSORT, Inc
$100
Regeneron Healthcare Solutions, Inc.
$97
GE HEALTHCARE
$96
CTI BioPharma Corp.
$94
ADC Therapeutics America, Inc.
$91
Seagen Inc.
$82
Kite Pharma, Inc.
$79
SERVIER PHARMACEUTICALS LLC
$72
Mirati Therapeutics, Inc.
$71
SpringWorks Therapeutics, Inc.
$64
EMD Serono, Inc.
$62
Sumitomo Pharma America, Inc.
$52
Sirtex Medical Inc
$51
PharmaEssentia USA Corporation
$39
Aurobindo Pharma USA, Inc.
$38
Lantheus Medical Imaging, Inc.
$38
Rigel Pharmaceuticals, Inc.
$35
PUMA BIOTECHNOLOGY, INC.
$31
TESARO, Inc.
$28
Alexion Pharmaceuticals, Inc.
$27
Spectrum Pharmaceuticals Inc.
$25
Catalyst Pharmaceuticals, Inc.
$22
Kyowa Kirin, Inc.
$22
Heron Therapeutics, Inc.
$20
Deciphera Pharmaceuticals Inc.
$20
Eisai Inc.
$19
EUSA Pharma (US) LLC
$17
Sun Pharmaceutical Industries Inc.
$15
AbbVie Inc.
$15
Agios Pharmaceuticals, Inc.
$15
Dendreon Pharmaceuticals LLC
$15
Myovant Sciences Inc.
$14
Karyopharm Therapeutics Inc.
$14
Bayer Healthcare Pharmaceuticals Inc.
$14
Servier Pharmaceuticals LLC
$14
JAZZ PHARMACEUTICALS INC.
$14
Secura Bio, Inc.
$13
Horizon Therapeutics plc
$12
Veracyte, Inc.
$2
Top 3 companies account for 28.0% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · Abraxane · Alecensa · Aliqopa · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · BYNFEZIA PEN · Balversa · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · CINVANTI · CYRAMZA · Cabometyx · DARZALEX · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · EVENITY · Enhertu · Erleada · FIRDAPSE · FRUZAQLA · Fabhalta · Farydak · Folotyn · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Inrebic · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · KRYSTEXXA · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MVASI · Marqibo · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Perjeta · Phesgo · Polivy · Pomalyst · QINLOCK · Quadramet · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SANDOSTATIN LAR · SARCLISA · SHINGRIX · SIR-Spheres Microspheres · SPRYCEL · Stivarga · Sylvant · TASIGNA · TECVAYLI · TEVIMBRA · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · Venclexta · Vonjo · XALKORI · XPOVIO · XTANDI · Yescarta · ZEJULA · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $6 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
14
Per 100K population
1.8
County median income
$73,099
Nearest hospital
PARK ROYAL HOSPITAL
4.4 mi
4.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Sooriyaarachchi is a mixed practice specialist, with above-average Medicare volume (top 20% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Sooriyaarachchi experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Sooriyaarachchi performed 31,110 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sooriyaarachchi receive payments from pharmaceutical companies?
Yes. Dr. Sooriyaarachchi received a total of $12,708 from 66 companies across 702 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sooriyaarachchi's costs compare to other hematologys in Cape Coral?
Dr. Sooriyaarachchi's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sooriyaarachchi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Cape Coral
Browse hematologys in Cape Coral ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology